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Notch is a family of transmembrane receptors that participate in the regulation of cell differentiation,
proliferation, and stemness. Notch pathway activation has also been found associated with different human
cancers including primary cutaneous T-cell lymphomas (CTCL). The elucidation of the mechanisms driving Notch
activation in these particular diseases has remained elusive. Here we studied the possibility that DNA
methylation at Notch pathway gene promoters and/or deregulation of Notch-associated microRNAs contribute to
activate Notch in mycosis fungoides (MF). By genome-wide DNA methylation analysis, we failed to detect any
consistent methylation at the Notch1, the Notch-ligand Jagged1, or the Notch-target Hes1 gene promoters, but
found a signiﬁcant methylation of the Notch-related microRNAs, in particular miR-200c and miR-124.
Downregulation of miR-200c is associated with overexpression of Jagged1, concomitant to Notch1 activation.
CTCL cell lines were infected with lentiviral vector encoding for miR-200c and ectopic expression of miR-200c in
CTCL lines resulted in Jagged1 protein downregulation associated with a reduction in the levels of active Notch1.
Our study deciphers an epigenetic mechanism regulating the Notch pathway in (MF) that might contribute to the
future design of more speciﬁc therapeutic strategies.
Journal of Investigative Dermatology (2015) 135, 3144–3152; doi:10.1038/jid.2015.328; published online 24 September 2015
INTRODUCTION
The molecular mechanisms responsible for the development
and progression of mycosis fungoides (MF) have not been
fully elucidated. Notch1 has focused interest in different forms
of cutaneous T-cell lymphomas (CTCL), as many Notch1
targets such as c-myc and BCL2 or components of the NF-κB
pathway are important for CTCL development or progression.
Notch1 is expressed and active in (MF), Sézary syndrome (SS)
(Kamstrup et al., 2010a), and primary cutaneous anaplastic
large-cell lymphomas (Kamstrup et al., 2008) and Notch1
activity prevents apoptosis in the CTCL cell lines (Kamstrup
et al., 2010a-b; Van der Fits et al., 2012).
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Notch is a family of transmembrane receptors that regulate
transcription of genes involved in embryonic development,
adult tissue homeostasis, cell differentiation, and survival.
There are four Notch receptors (Notch 1–4) and ﬁve ligands
(Jagged1–2 and Dll (Delta-like) 1, 2, and 4). Activation of
Notch receptors takes place after binding to one of their
ligands localized in the adjacent cell. Notch activation
depends on the release of the intracellular fragment ICN1 as
a result of its proteolytic processing by a multiprotein complex
with gamma-secretase activity. ICN1 is then translocated into
the nucleus where it interacts with the transcription factor
CBF1/RBPj and the co-activator Mastermind, leading to the
transcriptional induction of speciﬁc target genes. The best-
characterized Notch target genes include the HES (hairy
enhancer of split) and Herp/Hey families of basic helix-loop-
helix transcriptional repressors (Radtke and Raj, 2003).
In the hematopoietic system, Notch directly regulates the
differentiation and maturation of normal T lymphocytes, the
discrimination between the CD4 and CD8 lineages, and
the expression of TCRα/β receptors (Auderset et al., 2012). In
addition, regulatory T cells still express the Notch ligand
Jagged1 and its function is inhibited in vitro by blocking either
Notch1 or Jagged1. In general, Notch controls apoptosis
through pro-survival pathways such as phosphoinositide 3-
kinase and NF-κB (Espinosa et al., 2010). Notch1 was
originally identiﬁed in T-cell acute lymphoblastic leukemia
harboring the t(7;9) (q34;q34.3) translocation, which
generates a fusion protein with a segment of the T-cell
receptor. Activating mutations of the Notch1 protein, or/and
inactivation of Fbw7, the ubiquitin ligase responsible for
Notch degradation, have been identiﬁed as responsible for
most T-cell acute lymphoblastic leukemia cases in human
patients (Wang et al., 2011).
However, no speciﬁc mutations or chromosome transloca-
tions involving Notch1 have been found in CTCL and the
upstream regulators of Notch activity in these tumor cells
remain to be identiﬁed (Van der Fits et al., 2012). Speciﬁc
epigenetic mechanisms have been identiﬁed as responsible to
activate Notch signaling in different malignancies with no
detectable Notch genomic abnormalities (Wong et al., 2011).
Among them, CpG island methylation at both coding genes
and microRNAs have been associated with CTCL, but also
with other types of cancer (Esteller, 2008; Quintavalle et al.,
2013; Sandoval et al., 2015). Promoter DNA methylation is a
general epigenetic mechanism that has a central role in the
coordination of gene transcription in healthy normal cells.
Thus, alterations in the methylation patterns that impair the
transcriptional equilibrium greatly contribute to cancer
initiation and progression (Esteller, 2008).
The aim of this work is to investigate the Notch pathway
status in a series of samples from patients with MF tumor stage
(MFt) and to test the possibility that Notch activation in the
tumors was inﬂuenced by epigenetic modiﬁcations at
particular gene promoters. For such a purpose, we have here
studied the DNA promoter methylation pattern at several
Notch pathway components and known Notch-related
microRNAs using genome-wide DNA methylation bead chip
array. Our results indicate that epigenetic abrogation of
speciﬁc microRNAs determines the differential expression of
Notch ligands and subsequently Notch pathway activation
in MFt.
RESULTS
Activation of Notch1 associates with Jagged1 detection in MFt
By double direct immunoﬂuorescence using a speciﬁc
antibody against active Notch1 fragment (anti-ICN1) and
anti-CD3 (to identify the T lymphocytes), we detected that
most T cells of the tumor inﬁltrate expressed ICN1 in all tested
samples (Figure 1a). Jagged1 double direct immuno-
ﬂuorescence was observed in a comparable area of the same
tumor (Figure 1b). Tumor cell load was determined in
consecutive sections stained with hematoxylin and eosin
from all samples included in our study. All selected samples
disclosed a diffuse dense lymphoid inﬁltrate with > 70% of
atypical lymphocytes corresponding to histological features of
MFt (T3, tumor stage) with variable degree of large cell
transformation and few intermingled small/medium isolated
lymphocytes. Our results indicate that most T cells in our
samples, and in particular those containing high levels of
ICN1 and Jagged1, correspond to malignant T cells. Fluores-
cence pattern disclosing extensive ICN1 expression in
clustered large cells indicates that many neoplastic cells
express ICN1. We cannot determine whether the Notch
pathway is also activated in non-neoplastic or reactive T cells,
although we cannot rule out this possibility. However, other
T-cell populations were present very scarcely within the
inﬁltrate with few isolated (non-clustered) T cells including
CD8-positive or T-regulatory cells. Foxp3 staining was
performed and only scattered Foxp3 regulatory T cells were
detected within the tumor inﬁltrate (not depicted). Associated
with the presence of active ICN1, we detected by quantitative
reverse-transcription PCR (qRT–PCR) higher levels of the
Notch-ligand Jagged1 and the Notch-target Hes1 in MFt
samples compared with the control group of the inﬂammatory
dermatoses (IDs) (Figure 1c).
DNA methylation analysis of Notch-related genes and
microRNAs
Several epigenetically disrupted genes and microRNAs have
been identiﬁed in MFt (Gallardo et al., 2004; Jones et al.,
2012; Ferrara et al., 2014; Sandoval et al., 2015). Thus, we
analyzed the possible association between Notch activation
in MFt and the DNA methylation patterns at Notch1
pathway–associated genes. In a genome-wide DNA methyla-
tion analysis, we did not ﬁnd any relevant DNA methylation
difference in promoters of Notch1, Jagged1-2, Hes1, members
of Dll family, or Notch-regulator Fbxw7 (see complete list of
DNA-methylated Notch-related ligands or regulator genes in
Supplementary Table S1B online) in MFt patients with respect
to ID controls, indicating that other mechanisms should be
responsible for Notch1 pathway activation. Recent evidence
indicates that Notch pathway elements are regulated by
speciﬁc microRNAs (Ortega et al., 2015). These noncoding
RNAs interact with Notch signaling at different levels, leading
to tumorigenesis or chemoresistance (Mo et al., 2013). Thus,
we further analyzed the DNA methylation status at the
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promoter of microRNAs known to regulate particular Notch
pathway components. Unsupervised hierarchical clustering of
221 CpG islands located in the promoter region of 33 Notch-
related microRNAs resulted in the identiﬁcation of a
distinctive DNA methylation pattern in MFt samples com-
pared with the controls (Figure 2a). The most relevant
differentially methylated microRNAs that discriminated MFt
from ID were characterized by performing a supervised
analysis. Moreover, using a nonparametric Wilcoxon test
(delta average β-value40.2 and false discovery rate o5%),
we obtained a differentially methylated microRNA proﬁle that
clearly segregated MFt from ID controls, including 36 CpGs
that corresponded to 12 microRNAs (Figure 2b and Table 1).
Of note, miR-200c and miR-124-2/3 contained multiple
consecutive differentially methylated CpGs suggestive of
their functional involvement in MFt (Figure 3). Among
these microRNAs, miR-200c was considered of particular
interest, as it showed the higher differentially methylated
CpGs. We speciﬁcally focused on miR-200c, as it has a
central role in the regulation of Notch1 activation (by
controlling Jagged1 protein levels) (Vallejo et al., 2011;
Brabletz et al., 2011) and it is epigenetically inactivated in
different tumor types (Pieriaccioli et al., 2013). Other
members of the miR-200 family such as miR-200a and
miR-200b showed no distinctive methylation patterns in our
study. Strikingly, we previously reported that these micro-
RNAs are frequently located at regions with genomic
imbalances (Salgado et al., 2010).
Epigenetic regulation of miR-200c
We further analyzed whether DNA methylation of miR-200c
regulates its expression levels in MFt. After miR-200c
pyrosequencing analysis (see Supplementary Table S4
online), we found that miR-200c is methylated throughout
its promoter not only in MFt samples but also in the human
CTCL cell lines Myla, HuT-78, and HH (Figure 4a and
Supplementary Figure S1 online). Treatment of these cell lines
with the demethylating agent 5-aza-2'-deoxycytidine signiﬁ-
cantly increased the expression levels of miR-200c
(Figure 4b), indicating that DNA methylation has a functional
role in the transcriptional repression of miR-200c in MFt.
To validate this observation in MFt samples, we compared the
expression levels of miR-200c with the results obtained in the
DNA methylation array. This analysis demonstrated that MFt
samples (with hypermethylation of the miR-200c promoter)
showed a signiﬁcant reduction in miR-200c expression levels
when compared with the controls, strongly suggesting
that miR-200c is epigenetically regulated in MFt patients
(Supplementary Figure S2 online). Furthermore, qRT–PCR
analysis performed on an independent set of parafﬁn
MFt (n= 19) and ID (n=7) samples conﬁrmed that
miR-200c is downregulated in MFt when compared with ID
(Supplementary Figure S3 online).
Low levels of miR-200c drive Jagged1 upregulation in MFt
We aimed to investigate the putative relationship between
expression levels of miR-200c members and Jagged1 expression
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Figure 1. Notch1 and Notch ligand gene expression analyses. (a) Double immunoﬂuorescence expression showing nuclear localization of Notch1 detected with
anti-cleaved Notch1 (α-N1Icv, Cell Signaling at 1:200 in green) and anti-CD3 (Novocastra NCL-L-CD3-PS1, 1:400 in red) on mycosis funogides tumor stage (MFt)
samples. Nuclear control with 4',6-diamidino-2-phenylindole (DAPI) in blue. (b) T-cell population showing positive immunoﬂuorescence for the Notch ligand
Jagged1. (i/ii) Insets representing in detail representative immunoﬂuorescence results. (c) Upregulated expression levels of Jagged1 and Hes1 in MFt patients
compared with inﬂammatory dermatoses (IDs) are represented. Values were determined in triplicates by quantitative reverse-transcription PCR and are expressed
as mean± SEM. *Statistical signiﬁcance with Po0.05 using a nonparametric Mann–Whitney test.
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levels in a group of 11 MFt samples with available material.
Downregulation of miR-200c correlated with an increase in
Jagged1 expression levels as determined by a fold change41
in 8 out of the 11 MFt samples (73%) (Figure 5a). Moreover,
samples showing the lowest miR-200c expression levels
(cases 1, 3, 4, 9, 10, and 11) contained the highest amounts
of Jagged1, with a calculated fold change higher than 10.
We performed functional studies by transducing several
CTCL cell lines with a lentiviral vector encoding for
miR-200c. These experiments and the results are shown in
Figure 5b, demonstrating a direct functional link between
miR-200c attenuation, Jagged1 upregulation, and Notch1
activation in all tested CTCL cell lines. We found that ectopic
expression of miR-200c resulted in Jagged1 protein down-
regulation, as well as a reduction in the levels of active
Notch1 (as determined by Western blot (WB) with the speciﬁc
Notch1 Val1744 antibody, ICN1, detecting a single band at
110 kDa). The presence of the full-length Jagged1 band at
150 kDa was observed and, unexpectedly, CTCL cells
contained several additional bands with two different
antibodies against Jagged1 that were downregulated follow-
ing miR-200c transduction, associated with a reduction in the
levels of active Notch1 (Figure 5b). Our interpretation is that
those bands may correspond to truncated but functional
Jagged1 forms. In addition, we quantiﬁed P-STAT3 levels by
WB in CTCL cell lines and did not ﬁnd any difference
following ectopic mir200 expression. This is concordant with
reported data showing no cooperation between Notch1 and
STAT3 signaling pathways in SS (Van der Fits et al., 2012).
Altogether, our results indicate that miR-200c is epigenetically
repressed in MFt, leading to upregulation of Jagged1 and
Notch activation.
DISCUSSION
In this study we have conﬁrmed that Notch1 is active in MFt
samples, associated with increased levels of the Jagged1 ligand
and the Notch target Hes1. Moreover, we have deciphered a
potential epigenetic mechanism driving Nocth1 activation
through regulation of Jagged1 in MFt. We used a genome-
wide DNA methylation analysis to determine the promoter
methylation status of different Notch pathway components and
we did not ﬁnd differences in the methylation pattern of Notch
pathway genes when compared with controls. Recently, we
have reported a microRNA signature for MFt (Sandoval et al.,
2015), highly concordant with other reported in the literature
(Van Kester et al., 2011). No discordances were found in up- or
downregulated microRNAs and most of the upregulated
microRNAs in our cohort of MFt were described previously.
Among downregulated microRNAs we found unreported
microRNAs, which are interesting candidates with functional
impact in CTCL development (Manfè et al., 2010; Manfè et al.,
2012; Sandoval et al., 2015). Many of these microRNAs are
Notch related and we have now detected a distinctive signature
of microRNAs that are deregulated by promoter methylation
changes in MFt samples and cell lines derived from MF and
other CTCL. Particularly signiﬁcant was the identiﬁcation of
miR-200c and miR-124-2/3 as epigenetically silenced in MFt.
In recent years, Notch has been of increasing interest in
cancer and speciﬁc targeting therapies are now available.
Ongoing clinical trials are evaluating inhibitors of the gamma-
secretase complex active in both Notch and proteasome
inhibition (Biskup et al. 2013) or the blockage of Notch
receptor activation using speciﬁc peptides or recombinant
monoclonal antibodies. Notch activation has also been
implicated in several non-hematological and hematological
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Figure 2. Hierarchical clustering analysis and DNA methylation proﬁles of mycosis funogides tumor stage (MFt) patients and inﬂammatory dermatoses (IDs)
donors using Notch1-related microRNAs (miRNAs). (a) Unsupervised hierarchical clustering and heatmap associated with the methylation proﬁle (according to
the color scale shown) of the sample specimens based on the β-values of the 221 microRNA CpGs. Two different types of samples are represented: inﬂammatory
disease (IDs) and mycosis funogides tumor stage (MFt). (b) Supervised analysis differentiating MFt from IDs. Each column represents an individual patient and
each row an individual CpG.
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malignancies including Hodgkin’s lymphoma and systemic
anaplastic large-cell lymphoma, where it promotes cell
survival and proliferation through activation of the phosphoi-
nositide 3-kinase–Akt or NF-κB pathways (Ellisen et al.,1991;
Jehn et al., 1999; Pear and Aster 2004; Jundt et al., 2009;
Espinosa et al., 2010; Kamstrup et al. 2014).
The presence of active Notch1 in different forms of CTCL
has been described, showing some variability in expression in
the different reported studies. A strong nuclear expression of
Notch1 and the downstream Notch1 target gene Hes1 in
almost all the inﬁltrate in SS cases compared with psoriasis
or atopic dermatitis samples (Van der Fits et al., 2012).
In MF, a higher expression with the more advanced stage of
MF lesions (Kamstrup et al., 2010a) and a more intense
expression of Notch1 has been reported in cutaneous
anaplastic large-cell lymphomas compared with the more
Table 1. Differentially methylated CpGs identiﬁed in the comparison between MFt and IDs
Target ID Name UCSC name Group Island Control Tumor Delta (T-C) CHR MAPINFO Distance to TSS
cg24854681 MIR25 NR_029498 TSS200 0.43 0.74 0.31 7 99,691,314 − 131
cg22420044 MIR25 NR_029498 TSS200 0.37 0.61 0.23 7 99,691,385 − 202
cg22638766 MIR25 NR_029498 TSS1500 0.46 0.68 0.22 7 99,691,486 − 303
cg12616174 MIR124-1 NR_029668 TSS1500 Island 0.10 0.33 0.23 8 9,761,454 − 472
cg07792478 MIR124-2 NR_029669 TSS1500 Island 0.19 0.65 0.45 8 65,290,484 − 1222
cg10698928 MIR124-2 NR_029669 TSS1500 Island 0.05 0.38 0.33 8 65,290,320 − 1058
cg14590098 MIR124-2 NR_029669 TSS1500 Island 0.09 0.35 0.26 8 65,290,848 − 858
cg02226645 MIR124-2 NR_029669 TSS1500 S_Shore 0.13 0.40 0.27 8 65,291,287 − 419
cg04104463 MIR124-2 NR_029669 TSS1500 S_Shore 0.19 0.46 0.27 8 65,291,341 − 365
cg25900085 MIR124-2 NR_029669 TSS200 S_Shore 0.03 0.40 0.37 8 65,291,513 − 193
cg05474726 MIR124-2 NR_029669 TSS200 S_Shore 0.15 0.47 0.32 8 65,291,523 − 183
cg27313642 MIR124-2 NR_029669 TSS200 S_Shore 0.16 0.45 0.29 8 65,291,542 − 164
cg20653075 MIR124-2 NR_029669 TSS200 S_Shore 0.19 0.47 0.28 8 65,291,682 − 24
cg05455720 MIR124-2 NR_029669 TSS200 S_Shore 0.20 0.51 0.31 8 65,291,703 − 3
cg15699267 MIR124-3 NR_029670 TSS1500 Island 0.02 0.22 0.21 20 61,809,557 − 295
cg19267861 MIR124-3 NR_029670 TSS200 Island 0.12 0.39 0.26 20 61,809,724 − 128
cg03387135 MIR124-3 NR_029670 TSS200 Island 0.03 0.27 0.24 20 61,809,827 − 27
cg01052879 MIR124-3 NR_029670 TSS200 Island 0.06 0.31 0.25 20 61,809,830 − 24
cg18627360 MIR124-3 NR_029670 TSS200 Island 0.06 0.34 0.28 20 61,809,834 − 20
cg15028514 MIR124-3 NR_029670 TSS200 Island 0.12 0.33 0.21 20 61,809,841 − 13
cg24702147 MIR200C NR_029779 TSS1500 0.41 0.81 0.40 12 7,071,814 − 1048
cg00366413 MIR200C NR_029779 TSS200 0.41 0.74 0.33 12 7,072,696 − 166
cg27534624 MIR200C NR_029779 TSS200 0.53 0.82 0.29 12 7,072,727 − 135
cg22413603 MIR200C NR_029779 TSS200 0.43 0.75 0.32 12 7,072,765 − 97
cg01712737 MIR149 TSS1500 N_Shore 0.72 0.47 − 0.25 2 241,394,345 − 1073
cg01920129 MIR32 TSS1500 0.79 0.55 − 0.23 9 111,808,842 − 333
cg03369432 MIR340 TSS200 0.73 0.52 − 0.21 5 179,442,399 − 96
cg15516314 MIR433 TSS1500 N_Shore 0.86 0.60 − 0.26 14 101,347,290 − 933
cg23546343 MIR433 TSS1500 N_Shore 0.81 0.54 − 0.27 14 101,347,284 − 939
cg26931307 MIR495 TSS1500 0.83 0.63 − 0.20 14 101,499,620 − 472
cg27074221 MIR495 TSS200 0.77 0.46 − 0.31 14 101,500,080 − 40
cg21809913 MIR495 TSS200 0.82 0.62 − 0.20 14 101,500,052 − 12
cg05473648 MIR708 TSS200 0.81 0.57 − 0.24 11 79,113,178 − 112
cg25837979 MIR708 TSS1500 0.78 0.47 − 0.30 11 79,114,133 − 1067
cg04726985 MIR708 TSS1500 0.89 0.65 − 0.23 11 79,114,457 − 1391
cg23665802 MIR92A1 TSS1500 S_Shore 0.55 0.35 − 0.20 13 92,002,338 − 521
Abbreviation: MFt, mycosis fungoides tumor stage.
Different gene features are indicated as gene name, accession number, group, CpG island, average value for each group, delta values, chromosome location,
Map info, and distance to transcription start site. Red color indicates gain and green color indicates loss of methylation in MFt patients.
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benign pole lymphomatoid papulosis as well (Kamstrup et al.,
2008). A stage-speciﬁc expression of Notch1 has been
described for other cancers with prognostic implications
(Balink et al., 2005). The gamma-secretase inhibitors blocked
Notch1 signaling and potently induced apoptosis in cell lines
derived from MF (MyLa) (Kamstrup et al., 2010a) and SS
(SeAx, HuT-78), and also in primary leukemic Sézary cells
(Kamstrup et al., 2010a; Van der Fits et al., 2012). Speciﬁc
downregulation of Notch1 by small interfering RNA induced
apoptosis in SeAx cells linked to the inhibition of NF-κB,
one of the most important prosurvival pathway in CTCLs.
Notch1 and Jagged1 are also highly expressed in other
lymphoproliferative processes such as the cutaneous
anaplastic large-cell lymphomas (Kamstrup et al., 2008) and
gamma-secretase inhibitor treatment induces apoptosis in
cutaneous anaplastic large-cell lymphoma-derived cell lines
(Kamstrup et al., 2010b).
A consistent mechanism leading to Notch1 pathway
activation in MF and other CTCL has not been elucidated
yet, although genomic gains in the Notch1 locus have
occasionally been reported but no activating mutations have
been detected (Salgado et al., 2010; Van der Fits et al., 2012).
Apart from Notch1 gene mutations or genomic translocations
described in T-cell acute lymphoblastic leukemia, Notch1
activation seems to occur in many tumors as a consequence
of speciﬁc Notch1 ligand overexpression giving rise to the
cleavage of Notch1 intracellular domain and its translocation
into the nucleus. For example, in colon cancer harboring
APC mutations, beta-catenin activates Jagged1 expression,
which induces Notch activation (Rodilla et al., 2009). Notch
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Figure 3. Representation of speciﬁc promoter differentially methylated microRNAs. Schematic overview of three selected differentially methylated miRNAs
comparing CpGs DNA methylation levels between mycosis fungoides tumor stage (MFt) patients (violet) and inﬂammatory dermatosis donors (light blue)
throughout the promoter region. miR-200c and miR-124-2 show gain of methylation in MFt patients, whereas miR-495 shows loss of methylation. TSS
corresponds to transcription start site. *CpGs that show statistical signiﬁcance using a nonparametric Mann–Whitney U-test.
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Figure 4. DNA methylation–associated silencing of miR-200c in cutaneous
T-cell lymphoma (CTCL) cell lines. (a) DNA methylation levels of miR-200c
promoter determined by pyrosequencing. Data represent the mean of the
methylation level of two consecutive promoter CpGs. (b) Restored expression
of DNA methylated miR-200c in CTCL cell lines after treatment with the DNA
demethylating agent 5-aza-2′-deoxycytidine (AZA). Values were determined
in triplicates by quantitative reverse-transcription PCR and are expressed as
mean± SEM (n= 3). *Statistical signiﬁcance (Po0.05) with respect to
untreated cells (control) using a nonparametric Mann–Whitney test.
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signaling can be modulated by microRNAs targeting the
transcription factor Hes1 (miR-199) and the Notch ligand
Delta (miR-1) or by direct abrogation of the Noch-1 and
Notch-2 receptors (miR-34).
The miR-200 cluster, which targets Jagged1, has been
reported as a key regulator of the Notch pathway in
cancer (Wellner et al., 2009; Vallejo et al., 2011; Brabletz
et al., 2011). Importantly, here we have demonstrated that
epigenetic silencing of miR-200c may be sufﬁcient to
increase Jagged1 levels in MFt, leading to the activation of the
Notch1 pathway, and we did not ﬁnd any cooperation between
Notch1 and STAT3 signaling pathways in MF- and SS-derived
cell lines. We failed to demonstrate that other components
of the miR-200 family were epigenetically regulated.
Interestingly, these microRNAs are frequently located at
regions with genomic imbalances in MFt (Salgado et al.,
2010). Loss of miR-200 is commonly observed in advanced
tumors and has been reported as a clue mechanism
enhancing Notch activation through Jagged1 upregulation in
cancers, in which mutations in Notch pathway genes are
uncommon (Vrba et al. 2010; Brabletz et al., 2011; Vallejo
et al., 2011; Wang et al. 2011).
Another interesting regulator of Notch signaling in MFt
could be miR-124, which was previously identiﬁed as tumor
suppressor microRNA and its deregulation associated
with hematological cancers (Cao et al., 2013). Promoter
hypermethylation of miR-124 leads to reduced miR-124
expression in non-Hodgkin lymphomas (Wong et al., 2011).
Moreover, miR-124 was found to modulate the STAT3
pathway, which exerts an essential role in CTCL develop-
ment. Speciﬁcally, miR-124 inhibits STAT3 and reversed the
tumor-mediated immune suppression of T-cell proliferation
and induction of Foxp3+ regulatory T cells (Wei et al., 2013).
In conclusion, we have demonstrated that Notch1 signaling
is active in the lymphoid cells of MFt concomitant with
increased Jagged1 and Hes1 protein levels. Here we showed
that miR-200c is downregulated in MFt by promoter
methylation, which is functionally linked to Jagged1 upregu-
lation. We propose that restoring the expression levels of
miR-200c and other microRNAs targeting Notch1 could
represent a potential and a future therapeutic target in this
subtype of lymphomas.
MATERIALS AND METHODS
Study samples
A retrospective study with fresh-frozen archived samples was
conducted from patients diagnosed with MFt. The diagnosis was
established according to the World Health Organization/European
Organization for Research and Treatment of Cancer classiﬁcation
(Willemze et al., 2005). Twelve MFt samples were included in the
methylation array study. Control samples for the different study
methods included frozen samples from cutaneous inﬂammatory
diseases (IDs) showing a dense lymphocytic inﬁltrate (psoriasis,
n= 9) and validation data set that included an independent cohort
of parafﬁn-embedded MFt samples (n= 19) and ID controls
(psoriasis, n= 7).
Cell lines and treatments
Three representative human cancer CTCL cell lines (American Type
Culture Collection, Manassas, VA) Myla (MF), HuT-78 (SS), and HH
(aggressive non-MF CTCL) were used to evaluate the DNA
methylation status of selected Notch target microRNAs. To restore
the expression of DNA-methylated microRNAs, the cell lines were
treated with the DNA demethylating agent 5-aza-2′-deoxycytidine
(A3656, Sigma, St Louis, MO) at 3 μM for 72 hours.
Direct immunoﬂuorescence studies
Expression and subcellular localization of Notch1 were studied by
double direct immunoﬂuorescence evaluation on parafﬁn-embedded
samples with anti-cleaved Notch1 (rabbit monoclonal antibody
against ICN1 clone D3B8 Val1744, Cell Signaling Technology,
Danvers, MA) and anti-CD3 (Novocastra NCL-L-CD3-PS1, 1:400) for
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Figure 5. Epigenetic abrogation of miR-200c drives Jagged1 overexpression
and Notch1 pathway activation in mycosis funogides tumor stage (MFt). (a)
Comparative pattern of expression using relative fold change values between
Jagged1 and miR-200c. Gene and microRNA (miRNA) expression values in
each of the 11 MFt patients were normalized using the average value of
controls (inﬂammatory dermatosis donors). Relative fold change was
calculated by means of the ratio between Jagged1 and miR-200c.
Discontinuous horizontal line with the Jagged1/miR-200c ratio value=1
corresponds to controls. (b) Western blot analysis with the indicated
antibodies from different cell lines infected with the control or the lentiviral
vector encoding for miR-200c. It is noteworthy that the presence of the full-
length Jagged1 at 150 kDa and several additional bands corresponding to
functional Jagged1 fragments that are detected with two different antibodies
and are downregulated by miR-200c, coinciding with a reduction in the levels
of active Notch1 (ICN1). In contrast P-STAT3 levels remained constant.
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T-cell staining. After de-parafﬁnization, samples were treated with
citrate buffer pH 6.0 in autoclave for 20minutes at 60 Hz,
permeabilized, and incubated O/N at 4 °C with each antibody.
Process was carried out using tyramide-coupled to FitC at 1:500 in
ampliﬁcation solution (Perkin Elmer, Waltham, MA). Slides were
mounted with Vectashield plus 4',6-diamidino-2-phenylindole
mounting media (Vector Laboratories, Burlingame, CA).
Expression analysis by qRT–PCR
For coding genes: expression analyses of Notch ligand genes were
conﬁrmed by qRT–PCR. Total RNA was obtained in snap-frozen MFt
samples (n= 16) using the RNeasy Kit from Qiagen (Hilden,
Germany). For microRNAs: total RNA extraction from culture cell
lines was performed with the Genelute mammalian total RNA kit
(Sigma). Total RNA was extracted from 10× 10 μm parafﬁn-
embedded tissues from the retrospective patient cohort (validation
set for DNA methylation array study) using the commercial kit
(MirVanaTMmiRNA Isolation Kit) following the manufacturer’s
protocol (Ambion, Austin, TX).
RNA was quantiﬁed using a NanoDrop ND-1000 Spectrophot-
ometer (Axon Instruments, Sunnyvale, CA) and were analyzed using
the RNA Nano 6000 (Bioanalyzer 2100, Agilent Technologies, Palo
Alto, CA) in order to analyze the RNA integrity. Samples included in
the study had a quality index RIN (RNA integrity number) ≥ 6.
Complementary DNA retro-transcription was synthesized with the
qRT ﬁrst-strand complementary DNA synthesis kit (Amersham
Pharmacia Biotech, Piscataway, NJ) following the manufacturer’s
instructions. qRT–PCR in triplicates on the Light Cycler 480 (Roche
Molecular Systems Inc., Rotkreuz, Switzerland) was performed using
a TaqMan Universal PCR Master Mix kit and the ABI PRISM 7900HT
Sequence Detection System 7900HT (TaqMan microRNA assays,
Applied Biosystems, Foster City, CA) and ﬁnally analyzed with SDS
software. Each qRT–PCR product concentration (Ct) value was
normalized (threshold cycle) relative to endogenous controls.
For coding genes, keratin 14 (previously normalized by glycer-
aldehyde 3-phosphate dehydrogenase) was used to normalize
overexpression of Notch ligands from epidermal component in
healthy skin normalization data set and U48 was used in microRNA
quantiﬁcation. The 2-(ΔΔCt) method was used to determine relative
quantitative levels of each gene or microRNAs. In short, ΔCt=Ct
sample of interest—control Ct) and compared with control patient
samples (reference sample), by the method ΔΔCt (ΔΔCt=ΔCt
sample of interest—ΔCt reference sample).
Promoter methylation status analysis of Notch pathway
components and Notch-related microRNA
Methylation status of Notch pathway components and microRNA
promoter methylation analysis of previously identiﬁed Notch-related
microRNA presenting in the Inﬁnium Human Methylation 450 Bead
Chip from Illumina Inc., San Diego, CA were analyzed. The 450K
DNA Methylation array includes 485,764 cytosine positions of the
human genome. From these cytosine sites, 4,168 are associated to
noncoding RNA transcripts (1%), including 3,440 microRNAs that
correspond to 834 unique microRNAs (Sandoval et al., 2011). Thirty-
ﬁve Notch target microRNAs were selected based on literature or
microRNA.org database (http://www.microrna.org) (Supplementary
Table S1A online). After ﬁltering CpGs located in sex chromosomes,
we ended up with 221 CpGs located in the promoter region,
corresponding to 33 unique Notch target microRNAs (Supplementary
Table S2 online). On the other hand, we also analyzed Notch-related
17 genes (Supplementary Table S1B online) that corresponded with
559 CpGs in the analysis (Supplementary Table S3 online).
A subset of 21 samples (including 9 ID controls and 12 MFts) was
used for DNA methylation analysis. In short, DNA from these patients
was quantiﬁed by Quant-iT Pico Green dsDNA Reagent (Invitrogen,
Thermo Fisher Scientiﬁc, Inc., Waltham, MA) and the integrity was
analyzed in a 1.3% agarose gel. Bisulphite conversion of 600 ng of
each sample was performed according to the manufacturer’s
recommendation for Illumina Inﬁnium Assay. Effective bisulphite
conversion was checked for three controls that were converted
simultaneously with the samples. Four microliters of bisulphite-
converted DNA were used to hybridize on Inﬁnium Human
Methylation 450 Bead Chip, following Illumina Inﬁnium HD
Methylation protocol. Chip analysis was performed using Illumina
HiScan SQ ﬂuorescent scanner. The intensities of the images are
extracted using Genome Studio (2010.3) Methylation module (1.8.5)
software from Illumina. Methylation score of each CpG is represented
as β-value. For determining differentially methylated Notch target
microRNAs or genes, nonparametric Wilcoxon tests were applied.
Probes with multiple test–corrected P-value below 0.05 and a delta
value threshold of 0.2 in absolute value were used for selecting the
relevant CpGs. All statistical analyses were performed with the
Bioconductor project (v2.3) in the R statistical environment (v.2.8.1).
Pyrosequencing analysis
PCR for microRNAs was performed under standard conditions with
biotinylated primers using an annealing temperature of 60 °C.
Primer sequences for selected microRNAs are shown in
Supplementary Table S4 online. PCR products were observed at
2% agarose gels before pyrosequencing. Reactions were performed
in a PyroMark Q96 System version 2.0.6 (Qiagen) using appropriate
reagents and protocols, and the methylation value was obtained
from the average of the CpG dinucleotides included in the
sequence analyzed.
Ectopic expression of miR-200c in CTCL cell lines infected with
lentivirus encoding for miR-200c
Recombinant lentiviruses were produced by transient transfection of
HEK 293T cells according to Tronolab protocols (http://tronolab.epﬂ.
ch/page58122.html). Twenty micrograms of the transfer vector
(miR-200c from Sigma), 15 mg of the packaging plasmid (psPAX2),
and 6mg of the envelope plasmid (pMD2.G) were used. After 3 days,
the supernatant was ultracentrifuged and the viral pellet was
resuspended in 100ml of phosphate-buffered saline. Twenty micro-
liters of fresh viral suspension was used per infection.
Ethical considerations
The approval for the study was provided by the Comitè Ètic
d’Investigació Clínica from l’Insititut Municipal d’Assistència Sani-
tària (CEIC-PSMAR) and written informed consent was obtained from
all patients according to the national and international guidelines
(code of ethics, the Declaration of Helsinki Principles) and the legal
regulations on data privacy (Law 15/1999 of 13 December on the
Protection of Personal Data (Data Protection Act)) were considered.
All samples stored in the tumor bank (Hospital del Mar in Barcelona,
Spain) have the informed consent of patients.
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